...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Medical and Paediatric Oncology >Required treatment expenditures for Hepatitis C virus infection and advantage in the reduction of hepatocellular carcinoma incidence: Analysis of possible options in an endemic area
【24h】

Required treatment expenditures for Hepatitis C virus infection and advantage in the reduction of hepatocellular carcinoma incidence: Analysis of possible options in an endemic area

机译：丙型肝炎病毒感染的所需治疗支出和优势在减少肝细胞癌的发生率：分析地方性区域中可能的选择

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Hepatitis C virus (HCV) infection is a known underlying factor contributing to hepatocellular carcinogenesis. The use of direct-acting antiviral (DAA) medication is a form of clinical management for controlling HCV infection and reducing the hepatocellular carcinoma incidence. This medication is introduced to several endemic areas. The big concern is on the treatment expenditures. Several alternative options are proposed and it is required to assess the effect of each alternative option. Objective: Here, the authors assessed and estimated the required treatment expenditures for HCV infection and advantage in the reduction of hepatocellular carcinoma incidence based on the analysis of possible options in an endemic area. Methods: A medical economics analysis was done. Results: According to the cost–utility analysis, the best alternative option that is hereby recommended is DAA medication coverage for all cases. Conclusion: DAA medication coverage for all cases is recommended.
机译：背景：丙型肝炎病毒（HCV）感染是有助于肝细胞癌的已知潜在因素。使用直接作用抗病毒（DAA）药物是一种用于控制HCV感染并降低肝细胞癌发病率的临床管理形式。这种药物被引入了几个地方区域。令人担忧的是治疗支出。提出了几种替代方案，需要评估每个替代选项的效果。目的：此处，作者评估和估计了HCV感染所需的治疗支出以及在减少肝细胞癌发生时的优势，基于对地方性区域可能选择的分析。方法：进行了医学经济学分析。结果：根据成本实用性分析，特此建议的最佳替代方案是所有案例的DAA药物覆盖范围。结论：建议所有案例的DAA药物覆盖范围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号